chronic rhinitis
Conditions
Interventions
Group 1:Budesonide nasal spray
Group 2:Budesonide nasal spray+montelukast
Group 3:Budesonide nasal spray +Loratadine
Sponsors
Jinhua Hospital of Zhejiang University
Eligibility
Sex/Gender
All
Age
6 Years to No maximum
Inclusion criteria
Inclusion criteria: From July 2018 to July 21 Patients whose symptoms persisted or accumulated for more than 1 h per day were taken as the study subjects.
Exclusion criteria
Exclusion criteria: 1. Patients who have been treated with glucocorticoids, leukotriene receptor inhibitors, or antihistamines through the nasal cavity, oral cavity or systemic route in the past month; 2. Acute infectious diseases, upper respiratory tract infections or systemic inflammation symptoms such as fever and chills; 3. Structural rhinitis, nasal polyps, nasal masses and nasal mass lesions; 4. Pregnant and lactating women, patients with severe underlying diseases or mental disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cells of nasai smears; | — |
Countries
China
Contacts
Public ContactYaping Zou
Jinhua Hospital of Zhejiang University
Outcome results
None listed